Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer.
| Author | |
|---|---|
| Abstract |
:
The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1-2% of non-small cell lung cancer (NSCLC), conferring sensitivity to treatment with the ALK/ROS1/MET inhibitor crizotinib. Currently, insights into patterns of metastatic spread and mechanisms of crizotinib resistance among ROS1-positive patients are limited. |
| Year of Publication |
:
0
|
| Journal |
:
JCO precision oncology
|
| Volume |
:
2017
|
| Date Published |
:
2017
|
| Short Title |
:
JCO Precis Oncol
|
| Download citation |
